Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:796471.
doi: 10.1155/2015/796471. Epub 2015 Aug 9.

Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?

Affiliations

Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?

Pedro Weslley Rosario et al. Int J Endocrinol. 2015.

Abstract

Objective. To evaluate the percentage of elevated stimulated thyroglobulin (sTg) and persistent or recurrent disease (PRD) in patients with detectable basal Tg < 0.3 ng/mL. Methods. The sample consisted of 130 patients with papillary thyroid carcinoma (PTC) who were at low risk of PRD and who had neck ultrasound (US) without abnormalities, negative anti-Tg antibodies (TgAb), and detectable basal Tg < 0.3 ng/mL about 6 months after ablation. Results. sTg was <1 ng/mL in 88 patients (67.7%), between 1 and 2 ng/mL in 26 (20%), and ≥2 ng/mL in 16 (12.3%). Imaging methods revealed the absence of tumors in 16 patients with elevated sTg. During follow-up, Tg increased to 0.58 ng/mL in one patient and lymph node metastases were detected. Sixty-nine patients continued to have detectable Tg < 0.3 ng/mL and US revealed recurrence in only one patient. Sixty patients progressed to persistently undetectable Tg without apparent disease on US. Conclusions. In low-risk patients with PTC who have detectable basal Tg < 0.3 ng/mL after ablation, negative TgAb, and US, persistent disease is rare and eventual recurrences can be detected by basal Tg elevation and/or subsequent US assessments, with follow-up without sTg being an "alternative" to Tg stimulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Follow-up proposal for low-risk patients with detectable Tg < 0.3 ng/mL, negative circulating TgAb, and negative US after ablation. Tg, thyroglobulin; TgAb, anti-thyroglobulin antibodies; US, neck ultrasound. aThe algorithm does not apply to patients not submitted to ablation. bLow risk defined according to currently recommended classifications [3, 8]. cConsidering a second-generation assay with a functional sensitivity of 0.1 ng/mL. dAfter 5 years of stable detectable Tg and negative US, follow-up can be performed exclusively by annual measurement of basal Tg and imaging methods are only needed in the case of an increase.

References

    1. Pacini F., Castagna M. G., Brilli L., Pentheroudakis G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012;23(supplement 7):vii110–vii119. doi: 10.1093/annonc/mds230.mds230 - DOI - PubMed
    1. Rosário P. W., Ward L. S., Carvalho G. A., et al. Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. Brazilian Archives of Endocrinology and Metabolism. 2013;57(4):240–264. doi: 10.1590/s0004-27302013000400002. - DOI - PubMed
    1. Perros P., Boelaert K., Colley S., et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology. 2014;81(supplement 1):1–122. doi: 10.1111/cen.12515. - DOI - PubMed
    1. Giovanella L., Clark P. M., Chiovato L., et al. Diagnosis of endocrine disease: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. European Journal of Endocrinology. 2014;171(2):R33–R46. doi: 10.1530/EJE-14-0148. - DOI - PMC - PubMed
    1. Brassard M., Borget I., Edet-Sanson A., et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. Journal of Clinical Endocrinology and Metabolism. 2011;96(5):1352–1359. doi: 10.1210/jc.2010-2708. - DOI - PubMed

LinkOut - more resources